Centene Corporation, Molina Healthcare, and Caladrius Biosciences" name="Description" /> Centene Corporation, Molina Healthcare, and Caladrius Biosciences" /> Centene Corporation, Molina Healthcare, and Caladrius Biosciences" />

3 Health Management stocks to get rid of in July 2019

In this post we will go over 3 Health Management equities to potentially sell in July 2019. I will cover Centene Corporation, Molina Healthcare, and Caladrius Biosciences
Published over a year ago
View all stories for Macroaxis | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Ellen Johnson

This list of potential positions covers Healthcare providers, hospitals. Major hospitals and healthcare providers in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.
Story appears to be empty

Centene Corp (CNC)

The company has Return on Asset of 0.037 % which means that on every $100 spent on assets, it made $0.037 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1075 %, implying that it generated $0.1075 on every 100 dollars invested. Centene Corp's management efficiency ratios could be used to measure how well Centene Corp manages its routine affairs as well as how well it operates its assets and liabilities. At present, Centene Corp's Return On Assets are projected to increase slightly based on the last few years of reporting. At present, Centene Corp's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 6.4 B, whereas Net Tangible Assets are projected to grow to (1.4 B). This firm currently falls under 'Large-Cap' category with a total capitalization of 40.2 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Centene Corp's market, we take the total number of its shares issued and multiply it by Centene Corp's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be fairly valued. Centene Corp shows a prevailing Real Value of $78.57 per share. The current price of the firm is $75.58. Our model approximates the value of Centene Corp from analyzing the firm fundamentals such as Return On Equity of 0.11, profit margin of 0.02 %, and Current Valuation of 39.54 B as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor purchasing undervalued instruments and exiting overvalued instruments since, at some point, asset prices and their ongoing real values will blend.

Molina Healthcare (MOH)

The company has Return on Asset of 0.0743 % which means that on every $100 spent on assets, it made $0.0743 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.3039 %, implying that it generated $0.3039 on every 100 dollars invested. Molina Healthcare's management efficiency ratios could be used to measure how well Molina Healthcare manages its routine affairs as well as how well it operates its assets and liabilities. The Molina Healthcare's current Return On Capital Employed is estimated to increase to 0.43, while Return On Tangible Assets are projected to decrease to 0.07. As of now, Molina Healthcare's Other Current Assets are increasing as compared to previous years. The Molina Healthcare's current Non Current Assets Total is estimated to increase to about 2.5 B, while Intangible Assets are projected to decrease to under 120.3 M. The entity currently falls under 'Large-Cap' category with a total capitalization of 21.53 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Molina Healthcare's market, we take the total number of its shares issued and multiply it by Molina Healthcare's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Short Long Term Debt Total

2.5 Billion

As of now, Molina Healthcare's Short and Long Term Debt Total is increasing as compared to previous years.

Caladrius Biosciences (CLBS)

The company has return on total asset (ROA) of (16.73) % which means that it has lost $16.73 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (23.84) %, meaning that it generated substantial loss on money invested by shareholders. Caladrius Biosciences' management efficiency ratios could be used to measure how well Caladrius Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. This firm currently falls under 'Micro-Cap' category with a current market capitalization of 25.49 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Caladrius Biosciences's market, we take the total number of its shares issued and multiply it by Caladrius Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Current Health Management Recommendations

VolatilityHypeValuationAnalyst ConsensusFinancial LeverageOdds of DistressMacroaxis Advice
CDORO
Not Available
TFX
SHAC
Not Available

Watch out for price decline

Please consider monitoring Macroaxis on a daily basis if you are holding a position in it. Macroaxis is trading at a penny-stock level, and the possibility of delisting is much higher compared to other privates. However, just because the private is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Macroaxis stock to be traded above the $1 level to remain listed. If Macroaxis private price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is Macroaxis's Liquidity

Macroaxis financial leverage refers to using borrowed capital as a funding source to finance Macroaxis ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Macroaxis financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Macroaxis' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Macroaxis' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Macroaxis's total debt and its cash.
Story appears to be empty

Centene Corp (CNC)

The company has Return on Asset of 0.037 % which means that on every $100 spent on assets, it made $0.037 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1075 %, implying that it generated $0.1075 on every 100 dollars invested. Centene Corp's management efficiency ratios could be used to measure how well Centene Corp manages its routine affairs as well as how well it operates its assets and liabilities. At present, Centene Corp's Return On Assets are projected to increase slightly based on the last few years of reporting. At present, Centene Corp's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 6.4 B, whereas Net Tangible Assets are projected to grow to (1.4 B). This firm currently falls under 'Large-Cap' category with a total capitalization of 40.2 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Centene Corp's market, we take the total number of its shares issued and multiply it by Centene Corp's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be fairly valued. Centene Corp shows a prevailing Real Value of $78.57 per share. The current price of the firm is $75.58. Our model approximates the value of Centene Corp from analyzing the firm fundamentals such as Return On Equity of 0.11, profit margin of 0.02 %, and Current Valuation of 39.54 B as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor purchasing undervalued instruments and exiting overvalued instruments since, at some point, asset prices and their ongoing real values will blend.

Molina Healthcare (MOH)

The company has Return on Asset of 0.0743 % which means that on every $100 spent on assets, it made $0.0743 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.3039 %, implying that it generated $0.3039 on every 100 dollars invested. Molina Healthcare's management efficiency ratios could be used to measure how well Molina Healthcare manages its routine affairs as well as how well it operates its assets and liabilities. The Molina Healthcare's current Return On Capital Employed is estimated to increase to 0.43, while Return On Tangible Assets are projected to decrease to 0.07. As of now, Molina Healthcare's Other Current Assets are increasing as compared to previous years. The Molina Healthcare's current Non Current Assets Total is estimated to increase to about 2.5 B, while Intangible Assets are projected to decrease to under 120.3 M. The entity currently falls under 'Large-Cap' category with a total capitalization of 21.53 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Molina Healthcare's market, we take the total number of its shares issued and multiply it by Molina Healthcare's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Short Long Term Debt Total

2.5 Billion

As of now, Molina Healthcare's Short and Long Term Debt Total is increasing as compared to previous years.

Caladrius Biosciences (CLBS)

The company has return on total asset (ROA) of (16.73) % which means that it has lost $16.73 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (23.84) %, meaning that it generated substantial loss on money invested by shareholders. Caladrius Biosciences' management efficiency ratios could be used to measure how well Caladrius Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. This firm currently falls under 'Micro-Cap' category with a current market capitalization of 25.49 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Caladrius Biosciences's market, we take the total number of its shares issued and multiply it by Caladrius Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Current Health Management Recommendations

VolatilityHypeValuationAnalyst ConsensusFinancial LeverageOdds of DistressMacroaxis Advice
CDORO
Not Available
TFX
SHAC
Not Available

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Did you try this?

Run Portfolio Rebalancing Now

   

Portfolio Rebalancing

Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
All  Next Launch Module
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any private could be tightly coupled with the direction of predictive economic indicators such as signals in persons.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Other Consideration for investing

USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum